(ORLANDO, December 5, 2010) — Results from four innovative studies help answer outstanding questions about stem cell transplant procedures in treating various hematologic malignancies. Research will be presented today at the 52nd Annual Meeting of…
PHILADELPHIA — A research study from the Farber Institute for Neurosciences and the Department of Neuroscience at Thomas Jefferson University determines bone marrow stromal stem cells may aid in stroke recovery. The results can be found in Cell T…
Tampa, Fla. (Dec. 1, 2010) — The results of two studies published in the current issue of Cell Transplantation (19:9) using animal models of cerebral ischemia and ischemic stroke in rats may significantly impact the treatment of stroke in humans. …
HACKENSACK, N.J. (November 22, 2010) — The John Theurer Cancer Center at Hackensack University Medical Center announced today that it will present research updates and clinical trial results of 40 cutting-edge studies at the 52nd Annual American S…
A Mayo Clinic study is the first to show that for some patients with early stage multiple myeloma, the drug thalidomide may effectively delay the need for chemotherapy or more aggressive treatment for as much as two years. Multiple myeloma is an incurable cancer of the bone marrow. The final results of the nonrandomized phase II clinical trial were published today in the April issue of the journal Leukemia. Because of the promising indications, preliminary findings were released about a year ago.
Nearly one-third of patients with advanced multiple myeloma who had failed current standard therapy of chemotherapy or stem cell transplantation responded to thalidomide for a median duration of nearly one year in a Mayo Clinic study of the effects of thalidomide on myeloma. The findings are reported in the January issue of Mayo Clinic Proceedings.
Many studies in the last three years have determined that thalidomide is effective in the treatment of multiple myeloma, following the initial report by researchers at the University of Arkansas. However, information is limited on how long thalidomide therapy works and on survival rates with such therapy.